Entera Bio reports $12.2M net loss for 2021; guides FY2022 operating loss of $25-30M; EB613 Phase 3 trial in 2022

Entera Bio Ltd.

Revenue $571k in 2021 vs $365k in 2020; net loss $12.2M ($0.47 per share) vs $11.2M ($0.67 per share).
Cash $24.9M at Dec 31, 2021; $21.7M at Mar 1, 2022; expects FY2022 operating loss $25-30M.
EB613 (osteoporosis) Phase 3 pivotal trial expected to start in 2022 after positive FDA End of Phase 2 meeting.
EB612 (hypoparathyroidism) improved formulation; next clinical trial planned in 2022; Orphan Drug status FDA and EMA.
Engaged Torreya Capital as financial advisor for non-dilutive strategic alliances for EB613.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.